Benazepril patient counseling information: Difference between revisions
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) |
||
| Line 17: | Line 17: | ||
<u>'''Hyperkalemia'''</u>: Patients should be told not to use [[potassium]] supplements or salt substitutes containing potassium without consulting the prescribing physician. | <u>'''Hyperkalemia'''</u>: Patients should be told not to use [[potassium]] supplements or salt substitutes containing potassium without consulting the prescribing physician. | ||
<u>'''Neutropenia'''</u>: Patients should be told to promptly report any indication of infection (e.g., [[sore throat]], [[fever]]), which could be a sign of [[neutropenia]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LOTENSIN (BENAZEPRIL HYDROCHLORIDE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d954024-a191-46e3-ba71-2a7d5b0c65d5#nlm34067-9 | publisher = | date = | accessdate = }}</ref> | <u>'''Neutropenia'''</u>: Patients should be told to promptly report any indication of [[infection]] (e.g., [[sore throat]], [[fever]]), which could be a sign of [[neutropenia]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LOTENSIN (BENAZEPRIL HYDROCHLORIDE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d954024-a191-46e3-ba71-2a7d5b0c65d5#nlm34067-9 | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Revision as of 22:07, 11 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Amr Marawan, M.D. [2]
Patient Counseling Information
Information for Patients
Pregnancy: Female patients of childbearing age should be told about the consequences of exposure to Lotensin during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.
Angioedema: Angioedema, including laryngeal edema, can occur at any time with treatment with ACE inhibitors. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, eyes, lips, or tongue, or difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician.
Symptomatic Hypotension: Patients should be cautioned that lightheadedness can occur, especially during the first days of therapy, and it should be reported to the prescribing physician. Patients should be told that if syncope occurs, Lotensin should be discontinued until the prescribing physician has been consulted.
All patients should be cautioned that inadequate fluid intake or excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope.
Hyperkalemia: Patients should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.
Neutropenia: Patients should be told to promptly report any indication of infection (e.g., sore throat, fever), which could be a sign of neutropenia.[1]
References
Adapted from the FDA Package Insert.